Medical Device News Magazine

Linde Partners with 3D Medlab in Pioneering Research to Optimize 3D Printing of Complex Structures for Medical Devices

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Today Linde announced it has started pioneering research into how atmospheric conditions in the additive manufacturing process can be optimized to produce complex latticed structures for medical devices. In collaboration with 3D Medlab, a leader in additive manufacturing for the medical sector, the joint project is the first of its kind and represents a milestone in the field of orthopedic device development.

Multifaceted, latticed components aim to mimic human body parts and can better assimilate into the patient’s own bone and tissue structure, leading to fewer rejections and quicker healing times. Additive manufacturing can optimize the production of such components ensuring high-quality repeatability of the process and requiring less post-print finishing. However, the atmosphere in the printing chamber needs to be optimal and reproducible.

Atmospheric gases play a fundamental role in the printing process and any impurities that remain in the chamber, even once purged, can have a detrimental effect on the part being manufactured. Additionally, fumes created during the production process can remain on the part, requiring post-production cleaning.

Even extremely small variations in oxygen content can impair the mechanical or chemical properties of metals sensitive to oxygen – such as titanium and aluminum alloys – and can affect the composition of the end product. For the Linde/3D Medlab research trials, the titanium alloy in question is Ti-6AI-4V.

“We are proud to be collaborating with 3D Medlab on this important and forward-looking project,” said Pierre Forêt, Senior Expert Manufacturing, Linde. “As a customer at the forefront of medical device manufacturing, anything less than optimal product outcomes is critically important to avoid, so it is testament to our gases expertise and know-how that we have been selected to partner in this endeavor.”

The atmospheric trials involve a new helium/argon gas mixture created especially by Linde for the project to make the process smoother and cleaner, along with use of Linde’s ADDvance O2 precision, a first-of-a-kind oxygen measuring and analysis technology to ensure the optimal mix of gases within the print chamber. Along with the new gas mixture, ADDvance O2 precision will give 3D Medlab precise, granular control over the oxygen concentration and humidity levels in the print chamber.

“Our experience with Linde shows that they are as committed to the same high standards of precision and excellence in additive manufacturing that we are,” said Gaël Volpi, CEO, 3D Medlab. “Full regulatory compliance is a fundamental cornerstone in our engineering and design process and our customers trust us to ensure all proper measures and controls are in place.”

Linde began its association with 3D Medlab originally through the supply of its ADDvance powder cabinet, designed to retain the quality of valuable, sensitive metal powders used in the additive manufacturing process by protecting them from exposure to ambient air and humidity. While the current collaboration between Linde and 3D Medlab is focused on Ti-6AI-4V lattice structures, future efforts will include the potential of nickel titanium (also known as nitinol) in view of its excellent shape memory and super elasticity, making it an ideal candidate for next generation stents.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”